Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sovateltide - Midwestern University/Pharmazz

Next Previous
Drug Profile

Sovateltide - Midwestern University/Pharmazz

Alternative Names: IRL-1620; PMZ-1620; Sovatelitide; SPI-1620; Tycamzzi; Tyvalzi

Latest Information Update: 28 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Illinois at Chicago
  • Developer Pharmazz; Spectrum Pharmaceuticals
  • Class Antidementias; Antineoplastics; Imaging agents; Neuroprotectants; Peptides; Vascular disorder therapies
  • Mechanism of Action Angiogenesis modulating agents; Antioxidants; Apoptosis inhibitors; Diagnostic imaging enhancers; Endothelin B receptor agonists; Neurogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypovolaemic shock; Stroke
  • Phase III Ischaemic stroke; Solid tumours
  • Phase II Alzheimer's disease; Brain hypoxia-ischaemia; Spinal cord injuries
  • Discontinued Biliary cancer; Cerebrovascular disorders; Neurodegenerative disorders; Non-small cell lung cancer

Most Recent Events

  • 28 Jul 2026 No recent reports of development identified for phase-I development in Alzheimer's-disease in USA (IV, Injection)
  • 28 Jul 2026 No recent reports of development identified for phase-I development in Brain hypoxia-ischaemia in USA (IV, Injection)
  • 28 Jul 2026 No recent reports of development identified for phase-I development in Spinal-cord-injuries in USA (IV, Injection)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top